Immunotherapy targeting negative immune checkpoint regulators to enhance the anti-tumour immune response holds promise in the treatment of TNBC. V-domain Ig suppressor of T-cell activation (VISTA) is ...

In many malignancies, an increased number of tumor-infiltrating lymphocytes (TILs) is recognized as a favorable prognostic factor, with exceptions such as renal cell carcinoma. However, the clinical ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

SOUTH SAN FRANCISCO, Calif--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

Meet the Jekyll and Hyde of the immune system: activated CD8⁺ T cells. On June 24 in Nature Immunology, researchers led by Dorian McGavern at the National Institutes of Health introduce a granzyme ...

SAN MATEO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Asher Biotherapeutics (Asher Bio), a clinical-stage biotechnology company developing precisely-targeted immunotherapies for cancer, today announced ...

(A) CuN is formed by self-assembly of Cu²⁺ and NLG919 via Cu-N coordination bonds, with chemotherapeutic agents (e.g., β-lapachone) encapsulated through hydrophobic interactions. (B) Lap@CuN passively ...

A new Review reveals how aging can push the immune system into a paradoxical state, weaker against threats yet more prone to attacking the body’s own tissues.